文献速递心力衰竭与心肌病

EVAHEART I植入式左心室辅助装置治疗终末期心衰15例3年随访

[Long-term outcome of EVAHEART I implantable ventricular assist device for the treatment of end stage heart failure: clinical 3-year follow-up results of 15 cases].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2023-01-01

本研究回顾性分析阜外医院2018年1月至2021年12月连续15例接受EVAHEART I左心室辅助装置治疗的终末期心力衰竭男性患者,评估其长期有效性和安全性。结果显示装置植入后心功能、肝肾功能及生活质量显著改善,1年、2年、3年生存率分别为100%、87%和80%,不良事件经处理后多可治愈。

要点

  • 植入后1周LVEDD、BNP、总胆红素和肌酐较术前显著降低(P<0.05)。
  • 术后6个月15例患者NYHA分级均恢复至Ⅰ~Ⅱ级。
  • 1年、2年、3年生存率分别为100%、87%和80%。

核心结论

  • EVAHEART I植入式左心辅助系统可有效救治危重终末期心力衰竭患者,可长期携带生活并显著提高生存率,临床疗效明确。

研究设计与样本

  • 回顾性分析2018年1月至2021年12月阜外医院连续15例接受EVAHEART I左心室辅助装置治疗的终末期心力衰竭患者临床资料。
  • 15例均为男性,平均年龄(43.0±7.5)岁,其中扩张型心肌病11例、缺血性心肌病2例、瓣膜性心脏病2例。

主要发现

  • 植入后1周LVEDD由(80.93±6.69)mm降至(63.73±6.31)mm,BNP由(3 544.85±1 723.77)ng/L降至(770.80±406.39)ng/L,总胆红素由(21.28±10.51)μmol/L降至(17.39±7.68)μmol/L,肌酐由(95.82±34.88)μmol/L降至(77.32±43.81)μmol/L,P均<0.05。
  • 术前15例均为NYHA Ⅳ级,术后1个月9例恢复至Ⅲ级、3例至Ⅱ级、3例至Ⅰ级,术后6个月均恢复至Ⅰ~Ⅱ级。
  • 术后1个月6 min步行距离、生活质量总评分和视觉模拟评分较术前显著增加或改善(P<0.05)。
  • 1年、2年、3年生存率分别为100%、87%和80%,3例分别于术后412、610和872 d死于多器官功能衰竭。

关键数值与推荐

  • EVAHEART I转速1 700~1 950转/min,流量3.2~4.5 L/min,功耗3~9 W。
  • 长期携带期间3例于术后170、220和475 d发生驱动线缆感染,经换药治愈;1例因菌血症于术后155 d接受心脏移植。
  • 3例发生短暂性脑缺血发作,1例发生出血性脑卒中,均治愈未遗留后遗症。

临床怎么用

  • 对于依赖静脉血管活性药物的危重终末期心力衰竭患者,EVAHEART I可作为长期左心室辅助治疗选择。
  • 术后需长期监测驱动线缆感染、脑血管事件及机械故障等不良事件。

局限性

  • 本研究为单中心回顾性分析,样本量仅15例,均为男性,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the long-term efficacy and safety of the implantable ventricular assist system EVAHEART I in clinical use. Methods: Fifteen consecutive patients with end-stage heart failure who received left ventricular assist device therapy in Fuwai Hospital from January 2018 to December 2021 were enrolled in this study, their clinical data were retrospectively analyzed. Cardiac function, liver and kidney function, New York Heart Association (NYHA) classification, 6-minute walk distance and quality of life were evaluated before implantation and at 1, 6, 12, 24 and 36 months after device implantation. Drive cable infection, hemolysis, cerebrovascular events, mechanical failure, abnormally high-power consumption and abnormal pump flow were recorded during follow up. Results: All 15 patients were male, mean average age was (43.0±7.5) years, including 11 cases of dilated cardiomyopathy, 2 cases of ischemic cardiomyopathy, and 2 cases of valvular heart disease. All patients were hemodynamically stable on more than one intravenous vasoactive drugs, and 3 patients were supported by preoperative intra aortic balloon pump (IABP). Compared with before device implantation, left ventricular end-diastolic dimension (LVEDD) was significantly decreased ((80.93±6.69) mm vs. (63.73±6.31) mm, P<0.05), brain natriuretic peptide (BNP), total bilirubin and creatinine were also significantly decreased ((3 544.85±1 723.77) ng/L vs. (770.80±406.39) ng/L; (21.28±10.51) μmol/L vs. (17.39±7.68) μmol/L; (95.82±34.88) μmol/L vs. (77.32±43.81) μmol/L; P<0.05) at 1 week after device implantation. All patients in this group were in NYHA class Ⅳ before implantation, and 9 patients could recover to NYHA class Ⅲ, 3 to class Ⅱ, and 3 to class Ⅰ at 1 month after operation. All patients recovered to class Ⅰ-Ⅱ at 6 months after operation. The 6-minute walk distance, total quality of life and visual analogue scale were significantly increased and improved at 1 month after implantation compared with those before operation (P<0.05). All patients were implanted with EVAHEART I at speeds between 1 700-1 950 rpm, flow rates between 3.2-4.5 L/min, power consumption of 3-9 W. The 1-year, 2-year, and 3-year survival rates were 100%, 87%, and 80%, respectively. Three patients died of multiple organ failure at 412, 610, and 872 d after surgery, respectively. During long-term device carrying, 3 patients developed drive cable infection on 170, 220, and 475 d after surgery, respectively, and were cured by dressing change. One patient underwent heart transplantation at 155 d after surgery due to bacteremia. Three patients developed transient ischemic attack and 1 patient developed hemorrhagic stroke events, all cured without sequelae. Conclusion: EVAHEART I implantable left heart assist system can effectively treat critically ill patients with end-stage heart failure, can be carried for long-term life and significantly improve the survival rate, with clear clinical efficacy. 目的: 评价可植入式心室辅助系统EVAHEART I治疗心力衰竭的长期有效性和安全性。 方法: 连续纳入15例于2018年1月至2021年12月在阜外医院心外科接受左心室辅助装置EVAHEART I治疗的终末期心力衰竭患者,对其临床资料进行回顾性分析。评价植入左心室辅助装置前、术后1、6、12、24和36个月的心功能、肝肾功能、纽约心脏病协会(NYHA)分级、6 min步行距离、生活质量评分等。记录患者在长期携带左心室辅助装置期间有无驱动线缆感染、溶血、脑血管事件、机械故障、异常功耗增高、泵流量异常。随访1、2和3年生存率。 结果: 15例患者均为男性,平均年龄(43.0±7.5)岁,其中扩张型心肌病11例,缺血性心肌病2例,瓣膜性心脏病2例,所有患者血流动力学稳定均依赖1种以上静脉血管活性药物,3例患者行术前主动脉球囊反搏(IABP)支持。同植入装置前比较,患者植入后1周的左心室舒张末内径(LVEDD)显著减小[(80.93±6.69)mm比(63.73±6.31)mm,P<0.05],脑钠肽、总胆红素和肌酐均显著降低[(3 544.85±1 723.77)ng/L比(770.80±406.39)ng/L;(21.28±10.51)μmol/L比(17.39±7.68)μmol/L;(95.82±34.88)μmol/L比(77.32±43.81)μmol/L;P均<0.05]。本组15例患者术前NYHA分级均为NYHA Ⅳ级,术后1个月9例患者可恢复到NYHA Ⅲ级,3例恢复到Ⅱ级,3例恢复到Ⅰ级,术后6个月15例患者均恢复到Ⅰ~Ⅱ级;同术前相比较,患者植入术后1个月的6 min步行距离、生活质量总评分和视觉模拟评分均显著增加或改善(P<0.05)。15例患者植入EVAHEART I的转速在1 700~1 950转/min之间,流量3.2~4.5 L/min,功耗3~9 W,1、2和3年生存率分别为100%、87%和80%,3例患者分别于术后412、610和872 d死于多器官功能衰竭。在长期携带装置期间,3例患者分别于术后170、220和475 d发生驱动线缆感染,经换药治愈。1例患者因菌血症于术后155 d接受心脏移植。3例发生短暂性脑缺血发作,1例发生出血性脑卒中事件,均治愈未遗留后遗症。 结论: 植入式左心辅助系统EVAHEART I可有效救治危重终末期心力衰竭患者,可长期携带生活并显著提高生存率,临床疗效明确。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen, Wang, Du, et al. [Long-term outcome of EVAHEART I implantable ventricular assist device for the treatment of end stage heart failure: clinical 3-year follow-up results of 15 cases]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023. PMID: 37057326. doi:10.3760/cma.j.cn112148-20220614-00472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。